Searched for
SURESH SUBRAMANIAN
China pulls ahead in biologics race, forcing Indian drugmakers to rethink strategyIndia's drug companies face a tough race in the global biologics market. China is quickly becoming a leader in biotech supply chains. India...- India's over-the-counter drugs market to hit Rs 98,000 crore by 2030: ReportAn EY report estimated that India's OTC market, valued around Rs 47,000 crore in 2024, is projected to grow to Rs 98,000 crore around 13 pe...
- Tariff pause eases pressure on drug companiesIndian drug makers can breathe easier as the US reportedly shelves plans for tariffs on generic drug imports. This move is a significant re...
- Just like bad medicine...Trump tariff pricks again; India not seen badly hit by US’ latest salvoUS President Trump’s 100% tariff on pharmaceutical products targets only branded and patented drugs, leaving India’s generic exports largel...
- Trump’s 100% tariff spares Indian generics, but risks remain for pharma sectorUS President Donald Trump announced 100% tariffs on patented and branded drug imports. Indian generic drug makers face no immediate disrupt...
- China’s biotech is redrawing the global pharma map; what India can learnAmerican biggies are joining hands with Chinese companies. AbbVie signed a deal with Simcere Zaiming for a multiple myeloma treatment. Astr...
- India takes tiny steps back from its China dependencyIndia is striving to reduce its dependency on China for pharmaceutical raw materials by promoting domestic production through a Production-...
- Pharma raw material makers in race to tank up on CXO talentSome of these PE-owned platform companies include Advent International-led Cohance Lifesciences / Suven Pharma, PAG and CX Partners-funded ...
- Decoded: How India makes affordable drugs for developed world, but ‘deadly’ medicines for developing countriesIndia is called the 'pharmacy of the world' because it makes and exports drugs worth millions of dollars to many countries. But recent inci...
- Roche vs Indian Pharma: The battle for a cheaper cancer drugThe companies in the thick of it are Roche, a $51 billion Swiss pharma major, and Biocon, the Bengaluru-based company led by India’s first ...
- Buy Biocon Ltd. target Rs 1234.0 : Rakesh BansalBuy Biocon Ltd. at a price target of Rs 1234.0 and a stoploss at Rs 1107.0 from entry point
- Can nominated members continue to remain absent from RS, asks Naresh AgarwalAs many as 12 persons with special knowledge or practical experience on matters like literature, science, art and social service are nomina...
- Suresh Subramanian to head Biocon's branded formulations bizSuresh has over 30 years of experience in the pharmaceuticals market, having worked in India and Thailand for MNCs such as GlaxoSmithKline,...
- Criterion not met, no deemed status for Chinmaya universityThe ministry has now asked the Chinmaya Mission authorities to ensure compliance with the new regulations to be eligible for the deemed uni...
- Iconic brands like Corex, Becosule, Combiflam top chart of top 25 Indian drugsAccording to an audited retail sales data, all except two of the top 25 brands were launched prior to 2000 and some as early as the seventi...
- Olympus calls on Quatrro with $100-m investmentOlympus Capital has invested $100m in Raman Roy’s Quatrro BPO Solutions for a “significant minority stake” in the company.
Load More
